Metastatik Meme Kanserinde Kemik Metastazlarına Yaklaşım

Gennari A, Conte P, Rosso R, et al. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer. 2005;104(8):1742-1750. doi: 10.1002/cncr.21359.

Trayes KP, Cokenakes SEH. Breast Cancer Treatment. American Family Physician .2021;104(2):171-178.

Anders K, van de Poll-Franse LV, Creemers G-J, et al. Clinical management of women with metastatic breast cancer: a descriptive study according to age group. BMC Cancer. 2006;6(1):179. doi: 10.1186/1471-2407-6-179.

Kuchuk I, Hutton B, Moretto P, et al. Incidence, consequences and treatment of bone metastases in breast cancer patients-Experience from a single cancer centre. Journal of Bone Oncology. 2013;2(4):137-144. doi: 10.1016/j.jbo.2013.09.001.

Zhang H, Zhu W, Biskup E, et al. Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data. Journal of Bone Oncology. 2018;11:38-50. doi: 10.1016/j.jbo.2018.01.004.

Ihle CL, Wright-Hobart SJ, Owens P. Therapeutics targeting the metastatic breast cancer bone microenvironment. Pharmacology & Therapeutics. 2022;239:108280. doi: 10.1016/j.pharmthera.2022.108280.

Gampenrieder SP, Rinnerthaler G, Greil R. Bone-Targeted Therapy in Metastatic Breast Cancer - All Well-Established Knowledge?. Breast Care. 2014;9(5):323-330. doi:10.1159/000368710.

Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. Journal of Clinical Oncology. 2010;28(35):5132-5139. Epub 20101108. doi: 10.1200/jco.2010.29.7101.

Käkönen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer. 2003;97(3 Suppl):834–839. doi: 10.1002/cncr.11132.

Van Der Pluijm G, Sijmons B, Vloedgraven H, et al. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. Journal of Bone and Mineral Research. 2001;16(6):1077–1091. doi: 10.1359/jbmr.2001.16.6.1077.

Chirgwin JM, Guise TA. Molecular mechanisms of tumorbone interactions in osteolytic metastases. Critical Reviews in Eukaryotic Gene Expression. 2000;10(2):159–178.

Higgins LS, Vessella R, Corey E, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clinical Cancer Research. 2006;12 (20 Pt 2): 6213s-6216s. doi: 10.1158/1078-0432.CCR-06-1007.

Yin JJ, Selander K, Chirgwin JM, et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. Journal of Clinical Investigation. 1999;103(2):197-206. doi: 10.1172/JCI3523.

Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases. Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2001; 45(1):53-64.

Godersky JC, Smoker WR, Knutzon R. Use of magnetic resonance imaging in the evaluation of metastatic spinal disease. Neurosurgery. 1987;21(5):676-80. doi: 10.1227/00006123-198711000-00013.

Liu T, Wang S, Liu H, et al. Detection of vertebral metastases: a meta-analysis comparing MRI, CT, PET, BS and BS with SPECT. Journal of Cancer Research and Clinical Oncology. 2017;143(3):457-465. doi: 10.1007/s00432-016-2288-z.

Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich SE, Wong R, Hahn C. Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. Practical Radiation Oncology. 2017;7(1):4-12. doi: 10.1016/j.prro.2016.08.001.

Kiesel L, Kohl A. Role of the RANK/RANKL pathway in breast cancer. Maturitas. 2016;86:10-66. doi: 10.1016/j.maturitas.2016.01.001.

Wang L, Fang D, Xu J, Luo R. Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review. BMC Cancer.2020 ;20(1):1059. doi: 10.1186/s12885-020-07568-9.

Wu X, Li F, Dang L, et al. RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies. Frontiers in Cell and Developmental Biology. 2020;8:76. doi: 10.3389/fcell.2020.00076.

Qi WX, Tang LN, He AN, et al. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. International Journal of Clinical Oncology. 2014;19(2):403-410. doi: 10.1007/s10147-013-0561-6.

Quispe D, Shi R, Burton G. Osteonecrosis of the jaw in patients with metastatic breast cancer: ethnic and socio-economic aspects. The Breast Journal. 2011;17(5):510-3. Epub 20110715. doi: 10.1111/j.1524-4741.2011.01119.x.

Yarom N, Shapiro CL, Peterson DE, et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. Journal of Clinical Oncology. 2019;37(25):2270-2290. doi: 10.1200/JCO.19.01186.

Gennari A, André F, Barrios CH, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Annals of Oncology. 2021;32(12):1475-1495. doi: 10.1016/j.annonc.2021.09.019.

O'Carrigan B, Wong MH, Willson ML, et al. Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database of Systematic Reviews. 2017;10(10):CD003474. doi: 10.1002/14651858.CD003474.

Coleman R, Hadji P, Body JJ, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Bone health in cancer: ESMO Clinical Practice Guidelines. Annals of Oncology. 2020;31(12):1650-1663. doi: 10.1016/j.annonc.2020.07.019.

Amadori D, Aglietta M, Alessi B, et al. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncology. 2013;14(7):663-670. doi: 10.1016/S1470-2045(13)70174-8.

Hortobagyi GN, Van Poznak C, Harker WG, et al. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial. JAMA Oncology. 2017 ;3(7):906-912. doi: 10.1001/jamaoncol.2016.6316.

Himelstein AL, Foster JC, Khatcheressian JL, et al. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA. 2017;317(1):48-58. doi: 10.1001/jama.2016.19425.

Paterson AH, Powles TJ, Kanis JA, et al. McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology. 1993;11(1):59-65. doi: 10.1200/JCO.1993.11.1.59.

Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. British Journal of Cancer. 2004 ;90(6):1133-1137. doi: 10.1038/sj.bjc.6601663.

Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. New England Journal of Medicine. 1996;335(24):1785-91. doi: 10.1056/NEJM199612123352401.

Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. Journal of Clinical Oncology. 2010;28(35):5132-5139. doi: 10.1200/JCO.2010.29.7101.

Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. European Journal of Cancer. 2012;48(16):3082-3092. doi: 10.1016/j.ejca.2012.08.002.

Wajda BG, Ferrie LE, Abbott AG, et al. Denosumab vs. Zoledronic Acid for Metastatic Bone Disease: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cancers (Basel). 2025;17(3):388. doi: 10.3390/cancers17030388.